S-Phase Induction by Interleukin-6 Followed by Chemotherapy in Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin'S Lymphoma

References

• Callard R. E., Gearing A. J. H. The cytokines and their receptors. The Cytokine Facts Book, R. E. Callard, A. J. H. Gearing. Academic Press, London 1994; 31–97
   Google Scholar
• Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K, Kishimoto T. The essential role of B cell stirnulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 1988; 167: 332
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A, Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Jourdan M., Portier M, Bataille R. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr. Top. Microbiol. Immunol. 1990; 166, 23.
   Web of Science ®Google Scholar
• Heslop H. E., Bianchi A. C., Cordingley F. T., Turner M., Chandima W., De Mel C. P., Hofirand A. V., Brenner M. K. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J. Exp. Med. 1990; 172: 1729
   PubMed Web of Science ®Google Scholar
• Biondi A., Rossi V., Bassan R., Barbui T., Bettoni S., Sironi M., Mantovani A, Rambaldi A. Constitutive expression of the interleukind gene in chronic lymphocytic leukemia. Blood 1989; 73: 1279
   PubMed Web of Science ®Google Scholar
• Aderka D., Maor Y., Novick D., Engelmann H., Kahn Y., Levo Y., Wallach D, Revel M. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood 1993; 81: 2076
   PubMed Web of Science ®Google Scholar
• Van-Kooten C., Rensink I., Aarden L. & van-Oers R. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia 1993; 7: 618
   PubMed Web of Science ®Google Scholar
• Yee C., Biondi A., Wang X. H., Iscove N. N., De Sousa J., Aarden L. A., Wong G. G., Clark S. C., Messner H. A., Minden M. D. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989; 74: 798
   PubMed Web of Science ®Google Scholar
• Freeman G. J., Freedman A. S., Rabinowe S. N., Segil J. M., Horowitz J., Rosen K., Whitman J. F., Nadler L. M. Interleukin 6 gene expression in normal and neoplastic B cells. J. Clin. Invest. 1989; 83: 1512
   PubMed Web of Science ®Google Scholar
• Maksymiuk A. W., Bratvold J. S., Ezzat W., Tan L. K., Skinnider L. F. Non-Hodgkin's lymphoma in Saskatchewan. A review of 10 years' experience. Cancer 1994; 73: 711
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 1995; 333: 1052
   PubMed Web of Science ®Google Scholar
• Binet J. L. Treatment of chronic lymphocytic leukaemia. Chronic lymphocytic leukemia and related disorders, C Rozman, 1993; 867–878, In (. ed),. Baillière, London.
   Google Scholar
• Catovsky D, Murphy R. L. Key issues in the treatment of chronic lymphocytic leukaemia (CLL) [see comments]. Eur. J. Cancer 1995; 31, A, 2146.
   PubMedGoogle Scholar
• Montillo M., Tedeschi A., Delfini C., Olivieri A., Dadamo F. & Leoni P. Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia. Tumori. 1995; 81: 419
   PubMed Web of Science ®Google Scholar
• Carayon P, Bord A. Identification of DNA-replicat-ing lymphocyte subsets using a new method to label the bromo-deoxyuridine incorporated into the DNA. J. Immunol. Methods. 1992; 147: 225
   PubMed Web of Science ®Google Scholar
• Mortensen B. T., Schifter S., Pedersen L. B., Jensen A. N., Hovgaard D, Nissen N. I. Development and application of a sensitive radioimmunoassay for human granulo-cytemacrophage colony-stimulating factor able to measure normal concentrations in blood. Exp. Hematol. 1993; 21: 1366
   PubMed Web of Science ®Google Scholar
• Diamant M., Hansen M. B., Rieneck K., Svenson M., Yasukawa K, Bendtzen K. Stimulation of the B9 hybridoma cell line by soluble interleukin-6 receptors. J. Immunol. Methods. 1994; 173: 229
   PubMed Web of Science ®Google Scholar
• Drexler H. G., Brenner M. K., Coustan Smith E., Gignac S. M., Hoffbrand A. V. Analysis of signal transduction in B chronic lymphocytic leukemia cells. Blood 1988; 71: 1461
   PubMed Web of Science ®Google Scholar
• Jewell A. P., Lydyard P. M., Worman C. P., Giles F. J., Goldstone A. H. Growth Factors Can Protect B-Chronic Lymphocytic Leukaemia Cells Against Programmed Cell Death Without Stimulating Proliferation. Leuk. Lymphoma 1995; 18: 159
   PubMed Web of Science ®Google Scholar
• Weber J., Yang J. C., Topalian S. L., Parkinson D. R., Schwartzentruber D. S., Ettinghausen S. E., Gunn H., Mixon A., Kim H., Cole D., Levin R, Rosenberg S. A. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 1993; 11: 499
   PubMed Web of Science ®Google Scholar
• Gaillard J. P., Bataille R., Brailly H., Zuber C., Yasukawa K., Attal M., Maruo N., Taga T., Kishimoto T, Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur, J. Immunol. 1993; 23: 820
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Yong K. L., Panaytotidis P, Hoffbrand A. V. Interleukin-6 Inhibits Apoptosis and Tumour Necrosis Factor Induced Proliferation of B - Chronic Lymphocytic Leukaemia. Leuk. Lymphoma. 1996; 22: 83
   PubMed Web of Science ®Google Scholar
• Weber J., Gunn H., Yang J., Parkmson D., Topalian S., Schwartzentruber D., Ettinghausen S., Levitt D, Rosenberg S. A. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J. Immunother. Emphasis. Tumor, Immunol 1994; 15: 292
   PubMed Web of Science ®Google Scholar
• Van Gameren M. M., Willemse P. H., Mulder N. H., Limburg P. C., Groen H. J., Vellenga E, De Vries E. G. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994; 84: 1434
   PubMed Web of Science ®Google Scholar
• Veldhuis G. J., Willemse P. H., Sleijfer D. T., Van-Der-Grad W. T., Groen H. J., Limburg P. C., Mulder N. H., De-Vries E. G. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J. Clin. Oncol. 1995; 13: 2585
   PubMed Web of Science ®Google Scholar
• Demetri G. D., Bukowski R. M., Samueis B., Gordon M., Antman K., Mehca E. A., Samuel S., Campion M., Levitt D, Isaacs. R. Stimulation of Thrombopoiesis by Recombinant Human Interleukin-6 (IL6) Pre- and Post-Chemotherapy in F'reiously Untreated Sarcoma Patients with Normal Hematopoiesis. Blood 1993; 82, suppl I), 367a.
   PubMed Web of Science ®Google Scholar
• Ritch P. S., Schiller J., Rivkin S., Keever C., Witt P. L., Grossbem S. E., Breitmever J. B., Dreclisler D., Truitt R. L., Von Hoff D. D., Borden E. C. Phase I Evaluation of Recombinant Human Interleukin-6. Blood 1993; 82, suppl l), 367a.
   Web of Science ®Google Scholar
• Witzig T. E., Wiseman G., White C. A., Solinger A., Gordon L., Raubitschek A., Emmanoulides C., Royston I., Parker E., Chin P, Grillo-LÓPez A. IDEC-Y2B8 90Yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma:Interim results of a phase I/II trial. Blood 1997; 90(suppl 1), #2606a.
   Google Scholar
• Kaminski M. S., Vose J., Saleh M., Lister T. A., Box S., Crowther D., Zelenetz A. D., Colcher D, Wahl R. A multicenter phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients with Chemotherapy-relapsedrefractory low-grade or transformed low-grade B cell non-Hodgkin's lymphoma. Blood 1997; 90, (suppll), #2268a.
   Web of Science ®Google Scholar
• Ginaldi L., Martinis M., Matutes E., Faharat N., Morilla R, Catovsky D. CD19 and CD20 expression in chronic B cell leukaemias. Blood 1997; 90, (suppl 1), #40090B.
   Web of Science ®Google Scholar